Plan B: Is Behind-The-Counter Around The Corner?
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr’s Plan B meeting with FDA could yield a pharmacy-access sales format for an OTC version of the drug.
You may also be interested in...
Off The Slow Track? Plan B Resubmission Expected Within Two Weeks, Barr Says
The latest version of Barr's application will likely seek dual Rx/OTC status, with 18 as the age break for OTC sale.
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement